Home › NDC Lookup › RxCUI directory › RxCUI 1659800

Azelaic acid 150 MG/ML Topical Foam — RxCUI 1659800

RxNorm drug concept · Semantic clinical drug
RxCUI 1659800 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1659800
Official nameAzelaic acid 150 MG/ML Topical Foam
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asazelaic acid 15 % Topical Foam
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)4,542 prescriptions · 19 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Azelaic Acid Topical: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It's used to treat the red bumps and pimples that come with mild to moderate rosacea — a chronic skin condition that mainly affects the face. It's applied directly to the skin, not...
  • Yes, that's actually one of the most commonly reported side effects, especially in the first few weeks of use. It usually settles down as your skin adjusts. That said, if the irrit...
  • My skin is burning and stinging after I apply it — is that normal?
  • Shake the can well before each use. Gently wash your face with a mild cleanser, pat it dry, then apply a thin layer of foam to your whole face — cheeks, chin, forehead, and nose —...
📖 Read our full Azelaic Acid Topical guide →

🕸️ Concept Web — How Azelaic acid 150 MG/ML Topical Foam Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Azelaic acid 150 MG/ML Topical Foam RxCUI 1659800

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Azelate 618278
    • Azelaic acid 18602
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Finacea 352645
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Azelate Topical Foam 1659799
    • Azelaic acid Topical Foam 2647347
    • Azelate Topical Product 1155005
    • Azelaic acid Topical Product 2662121
    • Azelate Topical Foam [Finacea] 1659802
    • Azelaic acid Topical Foam [Finacea] 2658023
    • Finacea Topical Product 1168318
    • Topical Foam 346285
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Azelaic acid 150 MG/ML SCDC · 1659798
  • Azelate Topical Foam SCDF · 1659799
  • Azelaic acid Topical Foam SCDFP · 2647347
  • Azelate Topical Product SCDG · 1155005
  • Azelaic acid Topical Product SCDGP · 2662121

Brand-Name Concepts

  • Azelaic acid 150 MG/ML Topical Foam [Finacea] SBD · 1659803
  • Azelaic acid 150 MG/ML [Finacea] SBDC · 1659801
  • Azelate Topical Foam [Finacea] SBDF · 1659802
  • Azelaic acid Topical Foam [Finacea] SBDFP · 2658023
  • Finacea Topical Product SBDG · 1168318
  • Finacea BN · 352645

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 1659800 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
50222-0303-50 1 CAN in 1 CARTON (50222-303-50) / 50 g in 1 CAN FINACEA FOAM LEO Pharma Inc. 2018-10-01
50222-0303-91 1 CAN in 1 CARTON (50222-303-91) / 15 g in 1 CAN FINACEA FOAM LEO Pharma Inc. 2018-10-01
Observed labelers: LEO Pharma Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per gm · median
$8.3262
Range $8.3262–$8.3262 · middle 50% $8.3262–$8.3262 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.